ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms

ClinicalTrials.gov ID: NCT00401245

Public ClinicalTrials.gov record NCT00401245. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 8:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

The Effect of Dose Titration and Dose Tapering on the Tolerability of DVS SR in Women With Vasomotor Symptoms Associated With Menopause: The PRIMMUS (PRIstiq for Managing Menopause and Understanding Symptoms) Study

Study identification

NCT ID
NCT00401245
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
500 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • desvenlafaxine succinate sustained release Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2006
Primary completion
Dec 31, 2007
Completion
Dec 31, 2007
Last update posted
Oct 25, 2011

2006 – 2008

United States locations

U.S. sites
55
U.S. states
26
U.S. cities
47
Facility City State ZIP Site status
Pfizer Investigational Site Tucson Arizona 85710
Pfizer Investigational Site Tucson Arizona 85715
Pfizer Investigational Site Beverly Hills California 90211
Pfizer Investigational Site Encinitas California 92024
Pfizer Investigational Site Foothill Ranch California 92610
Pfizer Investigational Site San Diego California 92108
Pfizer Investigational Site San Diego California 92123
Pfizer Investigational Site Upland California 91786
Pfizer Investigational Site Denver Colorado 80218
Pfizer Investigational Site Longmont Colorado 80501
Pfizer Investigational Site Clearwater Florida 33761
Pfizer Investigational Site Crystal River Florida 34429
Pfizer Investigational Site DeLand Florida 32720
Pfizer Investigational Site Gainesville Florida 32606
Pfizer Investigational Site Lake Worth Florida 33461
Pfizer Investigational Site Miami Florida 33136
Pfizer Investigational Site Miami Florida 33143
Pfizer Investigational Site Miami Florida 33169
Pfizer Investigational Site Palm Harbor Florida 34684
Pfizer Investigational Site Tampa Florida 33606
Pfizer Investigational Site Idaho Falls Idaho 83404
Pfizer Investigational Site Champaign Illinois 61820
Pfizer Investigational Site Chicago Illinois 60612
Pfizer Investigational Site South Bend Indiana 46601
Pfizer Investigational Site Lexington Kentucky 40536
Pfizer Investigational Site Louisville Kentucky 40291
Pfizer Investigational Site Metairie Louisiana 70002
Pfizer Investigational Site Metairie Louisiana 70006
Pfizer Investigational Site Canton Michigan 48187
Pfizer Investigational Site Ypsilanti Michigan 48197
Pfizer Investigational Site Billings Montana 59101
Pfizer Investigational Site Omaha Nebraska 68131-2197
Pfizer Investigational Site Las Vegas Nevada 89128
Pfizer Investigational Site Lebanon New Hampshire 03755
Pfizer Investigational Site New Brunswick New Jersey 08901
Pfizer Investigational Site Albuquerque New Mexico 87106
Pfizer Investigational Site Albuquerque New Mexico 87131
Pfizer Investigational Site New York New York 10032
Pfizer Investigational Site Chapel Hill North Carolina 27514
Pfizer Investigational Site Charlotte North Carolina 28209
Pfizer Investigational Site Winston-Salem North Carolina 27103-4005
Pfizer Investigational Site Winston-Salem North Carolina 27103
Pfizer Investigational Site Bismarck North Dakota 58501
Pfizer Investigational Site Fargo North Dakota 58104
Pfizer Investigational Site Cleveland Ohio 44122
Pfizer Investigational Site Eugene Oregon 97401
Pfizer Investigational Site Pittsburgh Pennsylvania 15206
Pfizer Investigational Site Watertown South Dakota 57201
Pfizer Investigational Site Carrollton Texas 75006
Pfizer Investigational Site Houston Texas 77030
Pfizer Investigational Site Hurst Texas 76054
Pfizer Investigational Site Midland Texas 79705
Pfizer Investigational Site Norfolk Virginia 23502
Pfizer Investigational Site Norfolk Virginia 23507
Pfizer Investigational Site Seattle Washington 98105

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00401245, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 25, 2011 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00401245 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →